Perioperative Management of Tirzepatide for Spinal Cord Stimulator Implantation
Stop tirzepatide 4 days (approximately 96 hours) before the spinal cord stimulator procedure and restart once the patient is eating and drinking normally postoperatively, typically 24-48 hours after surgery.
Stopping Tirzepatide Before Surgery
Based on the most recent 2025 multidisciplinary consensus guidelines 1, tirzepatide requires specific perioperative management due to its prolonged half-life and effects on gastric emptying:
- Discontinue tirzepatide at least 4 days (96 hours) before the procedure 1
- This timing is based on tirzepatide's 5-day elimination half-life 1
- The goal is to minimize the risk of delayed gastric emptying and potential pulmonary aspiration during anesthesia
Rationale for This Timing
The consensus guidelines emphasize that tirzepatide, as a GLP-1/GIP receptor agonist, causes delayed gastric emptying that persists beyond standard fasting periods 1. While some early recommendations suggested stopping weekly GLP-1 receptor agonists one week before procedures, the 2025 guidelines provide more nuanced, drug-specific recommendations based on pharmacokinetic profiles. For tirzepatide specifically, with its 5-day half-life, a 4-day cessation period represents a pragmatic balance between minimizing aspiration risk and avoiding prolonged interruption of metabolic benefits 1.
Important Considerations During the Cessation Period
- Monitor blood glucose if the patient has diabetes, as tirzepatide provides significant glycemic control
- Ensure the patient maintains adequate hydration during the preoperative period
- The patient should follow standard preoperative fasting guidelines (typically nothing by mouth after midnight before surgery)
- Consider the anesthetic team's assessment of aspiration risk, particularly if the patient has additional risk factors
Restarting Tirzepatide After Surgery
Resume tirzepatide once the patient is eating and drinking normally, typically 24-48 hours after the spinal cord stimulator implantation 1.
Specific Restart Criteria
For patients discharged on the day of surgery:
- Restart when tolerating oral intake normally
- Usually within 24-48 hours postoperatively
For patients remaining hospitalized:
- Restart once eating and drinking normally
- Ensure no ongoing nausea, vomiting, or gastrointestinal complications
- Confirm the patient is medically stable
Clinical Pitfalls to Avoid
Do not restart tirzepatide if:
- The patient is experiencing postoperative nausea and vomiting
- Oral intake is not yet established
- There are concerns about gastroparesis or ileus
- The patient requires prolonged fasting for any reason
Key safety consideration: The most common adverse effects of tirzepatide are gastrointestinal (nausea, vomiting, diarrhea) 2, which can be exacerbated in the immediate postoperative period. Ensuring the patient has resumed normal eating patterns before restarting minimizes these risks.
Special Circumstances
If the Patient Has Diabetes
The perioperative cessation of tirzepatide requires particular attention in diabetic patients, as the drug provides substantial glycemic control 1. During the 4-day cessation period and immediate postoperative period:
- Implement alternative glucose management strategies
- Consider short-acting insulin coverage as needed
- Monitor blood glucose more frequently
Cardiovascular Considerations
Tirzepatide has demonstrated cardiovascular benefits 1, but the brief perioperative interruption (4 days before plus 1-2 days after) poses minimal cardiovascular risk. The priority remains preventing pulmonary aspiration, which carries significant morbidity and mortality risk (OR 10.23 for aspiration in elective surgery with GLP-1 receptor agonists) 1.
Weight Management Implications
For patients using tirzepatide primarily for weight management, reassure them that the brief interruption (approximately 5-6 days total) will not significantly impact their weight loss trajectory. The drug can be resumed at the same dose without re-titration after this short interruption.